Radiopharm Theranostics (RADX) Liabilities and Shareholders Equity (2024 - 2025)
Radiopharm Theranostics (RADX) reported Liabilities and Shareholders Equity of $553858.6 for Q2 2025, up 16.67% year-over-year from $474737.2 in Q2 2024, and up 16.67% quarter-over-quarter from $474737.2 in Q2 2024.
Radiopharm Theranostics (RADX) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $553858.6 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Radiopharm Theranostics | 5.82 Bn | 5.81 Bn | - | 553,858.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 553,858.65 |
| Jun 30, 2024 | 474,737.15 |